InsidersTradesSigma
Total declarations
Companies
▲ Purchases (29 ops.)
▼ Sales (0 ops.)
Discover the complete record of transactions filed by RAMSAY DAVID A, Independent Director. Officer active across 3 companies, notably Savara Inc. In total, 29 reports have been recorded. Total volume traded: €801k. The latest transaction was filed on 17 June 2022 — Acquisition. Regulator: SEC (Form 4). The full history is free.
Declarations29 total
€50,17239,906 shares@ €1.25720.0041% mcap11.0% of flow
Common Stock
SEC:0001209191-22-038640:0·
Ideal exit: 14 Mar 2023 (T+270)
€16,50515,000 shares@ €1.10030.0016% mcap6.3% of flow
Common Stock
SEC:0001209191-21-071589·
Ideal exit: 25 Sept 2022 (T+270)
€16,50515,000 shares@ €1.10030.0013% mcap3.6% of flow
Common Stock
SEC:0001209191-21-071589:0·
Ideal exit: 25 Sept 2022 (T+270)
€14,43915,000 shares@ €0.96260.0014% mcap5.5% of flow
Common Stock
SEC:0001209191-21-070142·
Ideal exit: 11 Sept 2022 (T+270)
€14,43915,000 shares@ €0.96260.0012% mcap3.2% of flow
Common Stock
SEC:0001209191-21-070142:0·
Ideal exit: 11 Sept 2022 (T+270)
€32,20035,000 shares@ €0.920.0031% mcap12.3% of flow
Common Stock
SEC:0001209191-21-069189·
Ideal exit: 6 Sept 2022 (T+270)
€32,20035,000 shares@ €0.920.0026% mcap7.1% of flow
Common Stock
SEC:0001209191-21-069189:0·
Ideal exit: 6 Sept 2022 (T+270)
€10,98611,843 shares@ €0.92760.0011% mcap4.2% of flow
Common Stock
SEC:0001209191-21-068660·
Ideal exit: 3 Sept 2022 (T+270)
€10,98611,843 shares@ €0.92760.0009% mcap2.4% of flow
Common Stock
SEC:0001209191-21-068660:0·
Ideal exit: 3 Sept 2022 (T+270)
€5,2191,601 shares@ €3.259912.5% of flow
Common Stock
SEC:0001209191-21-068221·
Ideal exit: 29 Aug 2022 (T+270)
€5,2191,601 shares@ €3.25996.3% of flow
Common Stock
SEC:0001209191-21-068221:0·
Ideal exit: 29 Aug 2022 (T+270)
€3,4373,606 shares@ €0.95320.0003% mcap1.3% of flow
Common Stock
SEC:0001209191-21-067437·
Ideal exit: 28 Aug 2022 (T+270)
€3,4373,606 shares@ €0.95320.0003% mcap0.8% of flow
Common Stock
SEC:0001209191-21-067437:0·
Ideal exit: 28 Aug 2022 (T+270)
€15,40016,000 shares@ €0.96250.0015% mcap5.9% of flow
Common Stock
SEC:0001209191-21-067244·
Ideal exit: 27 Aug 2022 (T+270)
€15,40016,000 shares@ €0.96250.0012% mcap3.4% of flow
Common Stock
SEC:0001209191-21-067244:0·
Ideal exit: 27 Aug 2022 (T+270)
€57,53560,200 shares@ €0.95570.0056% mcap22.1% of flow
Common Stock
SEC:0001209191-21-066037·
Ideal exit: 15 Aug 2022 (T+270)
€57,53560,200 shares@ €0.95570.0047% mcap12.6% of flow
Common Stock
SEC:0001209191-21-066037:0·
Ideal exit: 15 Aug 2022 (T+270)
€28,0237,500 shares@ €3.736467.2% of flow
Common Stock
SEC:0001209191-21-065859·
Ideal exit: 14 Aug 2022 (T+270)
€28,0237,500 shares@ €3.736433.6% of flow
Common Stock
SEC:0001209191-21-065859:0·
Ideal exit: 14 Aug 2022 (T+270)
€43,49039,552 shares@ €1.09960.0042% mcap16.7% of flow
Common Stock
SEC:0001209191-21-058141·
Ideal exit: 25 Jun 2022 (T+270)
€43,49039,552 shares@ €1.09960.0035% mcap9.5% of flow
Common Stock
SEC:0001209191-21-058141:0·
Ideal exit: 25 Jun 2022 (T+270)
€66,78366,554 shares@ €1.00340.0065% mcap25.6% of flow
Common Stock
SEC:0001209191-21-052653·
Ideal exit: 14 May 2022 (T+270)
€66,78366,554 shares@ €1.00340.0054% mcap14.6% of flow
Common Stock
SEC:0001209191-21-052653:0·
Ideal exit: 14 May 2022 (T+270)
€8,4493,000 shares@ €2.816320.3% of flow
Common Stock
SEC:0001209191-21-036024·
Ideal exit: 18 Feb 2022 (T+270)
€8,4493,000 shares@ €2.816310.1% of flow
Common Stock
SEC:0001209191-21-036024:0·
Ideal exit: 18 Feb 2022 (T+270)
25 of 29 declarations
About RAMSAY DAVID A
David A. Ramsay is an experienced biopharmaceutical executive and an Independent Director at Savara Inc., where he has served on the board since April 2017. His career has been built around corporate finance, development strategy, and governance in the life sciences sector. At Savara, he brings extensive experience in capital markets, financial oversight, and strategic board-level judgment, which are particularly valuable for a publicly traded clinical-stage biotechnology company. Prior to Savara, Mr. Ramsay held senior leadership positions at Halozyme Therapeutics, Inc., where he served first as Chief Financial Officer and later as Vice President, Corporate Development. That combination gave him both a finance and strategic transactions perspective. During his time at Halozyme, he helped support the company through important growth and commercialization phases, with responsibilities spanning financial management, corporate planning, and broader development initiatives. He also served as Senior Vice President and Chief Financial Officer of Bonti, Inc., a private biotechnology company focused on neurotoxin-based products for therapeutic and aesthetic applications. That role added further experience in clinical-stage biotech operations, private-company financing, and the execution challenges facing emerging life sciences businesses. Earlier in his career, Mr. Ramsay was Chief Financial Officer of Lathian Systems, Inc. He then moved to Valeant Pharmaceuticals International, Inc. (formerly ICN Pharmaceuticals), where he served as Vice President, Treasurer and Director, Corporate Finance. He began his professional career at Deloitte & Touche, where he earned his CPA license. This progression reflects a consistent career path across audit, treasury, finance leadership, and corporate development. He also served on the board of La Jolla Pharmaceutical Company until its acquisition in 2022, reinforcing his experience as a director within publicly listed pharmaceutical companies. At Savara, his contribution is typically associated with independent oversight, financial discipline, and informed governance. Overall, David A. Ramsay is best understood as a seasoned biotech finance and board leader with deep experience in U.S. public-company governance, corporate finance, and strategic execution in healthcare.
